These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 24329800)
1. Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers. Ghosh A; Holland AM; van den Brink MR Immunol Rev; 2014 Jan; 257(1):226-36. PubMed ID: 24329800 [TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796 [TBL] [Abstract][Full Text] [Related]
3. Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. Ghosh A; Dogan Y; Moroz M; Holland AM; Yim NL; Rao UK; Young LF; Tannenbaum D; Masih D; Velardi E; Tsai JJ; Jenq RR; Penack O; Hanash AM; Smith OM; Piersanti K; Lezcano C; Murphy GF; Liu C; Palomba ML; Sauer MG; Sadelain M; Ponomarev V; van den Brink MR J Clin Invest; 2013 Jun; 123(6):2654-62. PubMed ID: 23676461 [TBL] [Abstract][Full Text] [Related]
4. Cytolytic pathways in haematopoietic stem-cell transplantation. van den Brink MR; Burakoff SJ Nat Rev Immunol; 2002 Apr; 2(4):273-81. PubMed ID: 12001998 [TBL] [Abstract][Full Text] [Related]
5. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. Zilberberg J; Feinman R; Korngold R Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643 [TBL] [Abstract][Full Text] [Related]
6. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets. Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450 [TBL] [Abstract][Full Text] [Related]
8. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075 [TBL] [Abstract][Full Text] [Related]
9. The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity. Wang H; Yang YG Immunol Rev; 2014 Mar; 258(1):30-44. PubMed ID: 24517424 [TBL] [Abstract][Full Text] [Related]
10. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation. Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768 [TBL] [Abstract][Full Text] [Related]
11. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation. Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation. Du W; Cao X Front Immunol; 2018; 9():2979. PubMed ID: 30631325 [TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
15. Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking. Hu R; Liu Y; Song Y; Su M; Lu X; Rood D; Lai L Br J Haematol; 2016 Nov; 175(3):505-516. PubMed ID: 27447780 [TBL] [Abstract][Full Text] [Related]